{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-assessment/management/prescribing-to-young-people/","result":{"pageContext":{"chapter":{"id":"04a5ef68-fad9-5897-8a64-10294e5004a2","slug":"prescribing-to-young-people","fullItemName":"Scenario: Prescribing to young people","depth":2,"htmlHeader":"<!-- begin field 2959be08-dedb-408b-adbc-6ca3188a5c92 --><h2>Scenario: Prescribing to young people</h2><!-- end field 2959be08-dedb-408b-adbc-6ca3188a5c92 -->","summary":"Covers the choice of contraception for girls aged under 18 years.","htmlStringContent":"<!-- begin item bb640906-18b6-4535-9f55-cd3ad036b15c --><!-- begin field 8f9af02f-b33a-4ad6-88e2-acbc015a3ec3 --><p>From age 13 years to 60 years (Female).</p><!-- end field 8f9af02f-b33a-4ad6-88e2-acbc015a3ec3 --><!-- end item bb640906-18b6-4535-9f55-cd3ad036b15c -->","topic":{"id":"b3143012-a228-55f5-8507-b5b650690e4c","topicId":"32f1df2c-afc0-4f35-be88-49caf8770b41","topicName":"Contraception - assessment","slug":"contraception-assessment","lastRevised":"Last revised in September 2019","chapters":[{"id":"8d7c8a25-4e93-5a42-928f-f6611bb74f8b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f6467a38-cb74-5956-9113-c5ea6b3e26b3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6121a83b-02e9-52ac-a8f9-0998004484bc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"07b5f362-627f-5d8a-8d01-b917142582c2","slug":"changes","fullItemName":"Changes"},{"id":"0df9a885-e331-5bb2-aa56-e9c271c953dc","slug":"update","fullItemName":"Update"}]},{"id":"699be09a-1785-5ab5-bf3b-cf106ce69b83","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59c7a2c-4736-5055-b01b-29e6039bc23b","slug":"goals","fullItemName":"Goals"},{"id":"8e96e0e4-38c0-5981-bfd3-d340e227337e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df0725fd-cf61-5019-a02b-7c6e05ca6d55","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"86b18852-547f-5859-960f-b4512c2736c1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"61cea463-ab64-5105-8179-666b624b775b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8d52411f-5b91-53ff-87d9-703de7ff4ff1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6a02d9d-3223-585d-89bb-915cc73d1565","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6218ca2-8f9c-534f-95be-c1a373a78494","slug":"comparative-effectiveness-of-contraceptive-methods","fullItemName":"Comparative effectiveness of contraceptive methods"},{"id":"1e7241c0-cd2e-5c44-a7d0-01f505a5f6df","slug":"available-contraceptive-methods-in-the-uk","fullItemName":"Available contraceptive methods in the UK"}]},{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"de31dc4a-7073-5d0b-83fb-9e0af6e49a7b","slug":"issues-to-consider-discuss","fullItemName":"Scenario: Issues to consider and discuss"},{"id":"10acf1be-13df-5c89-8f9c-6c905784040b","slug":"comorbidities-special-situations","fullItemName":"Scenario: Comorbidities and special situations"},{"id":"04a5ef68-fad9-5897-8a64-10294e5004a2","slug":"prescribing-to-young-people","fullItemName":"Scenario: Prescribing to young people"},{"id":"012d4729-63d2-51ca-a18c-bbd593b74fa4","slug":"approaching-the-menopause","fullItemName":"Scenario: Approaching the menopause"},{"id":"5970d6e3-da30-5c77-b143-090babc6df1b","slug":"assessment-for-specific-contraceptive-methods","fullItemName":"Scenario: Assessment for specific contraceptive methods"}]},{"id":"1f285502-649a-5805-a56d-1819aafe2ef0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2c624d48-ad5c-53e5-afd7-03cbcb0af45d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"040eb257-bbbd-5695-8eda-cde5a6b0991e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"582f4ca4-299f-54d7-ac03-285acee6a6d6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c6171063-570c-5710-a837-052779620da6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"278eb9ce-8d46-577d-bc1b-19866cb57433","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7e6a7d96-a9eb-5bb8-bb74-9a82eb3efeaa","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"83baf2bb-d418-5417-9e87-94f055e1ea8a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"5dcf2749-754f-5c14-a5ef-3f31e4f26c6a","slug":"choice-of-method-for-girls-under-18-years","fullItemName":"Choice of method for girls under 18 years","depth":3,"htmlHeader":"<!-- begin field 778cc56e-0da8-40c0-b4e6-96ef25389239 --><h3>What do I need to consider when prescribing contraceptives to girls under 18 years of age?</h3><!-- end field 778cc56e-0da8-40c0-b4e6-96ef25389239 -->","summary":null,"htmlStringContent":"<!-- begin item 8adab1d7-66d0-4934-a7ae-1ac28861d3f7 --><!-- begin field 46c7fd41-5b8e-43a6-8af4-7b05b321d520 --><ul><li>Provided that there are no medical contraindications, a girl can use her chosen method of contraception.</li><li><strong>Before menarche:</strong><ul><li>Avoid the use of regular hormonal contraception in sexually active girls who have not started menstruating.</li><li>Recommend the use of condoms both as a contraceptive, and to prevent sexually transmitted infections (STIs).</li></ul></li><li><strong>From menarche to 17 years of age</strong>, discuss the following methods of contraception, taking into account her personal circumstances, and how important it is that she avoids pregnancy: <ul><li>Barrier methods (condoms, diaphragms, and caps). </li><li>Combined oral contraceptive (COC) pills, combined transdermal patch (CTP), or combined vaginal ring (CVR).</li><li>Progestogen-only pill (POP), progestogen-only injectables, or progestogen-only implants.</li><li>Copper intrauterine device (Cu-IUD) or the levonorgestrel intrauterine system (LNG-IUS).</li></ul></li><li><strong>Advise young people:</strong><ul><li>About the correct and consistent use of condoms to reduce the risk of STIs.</li><li>To get tested for STIs 2 weeks after unprotected sexual intercourse (UPSI) to detect any newly acquired infection, and also 12 weeks after UPSI, as it may take time for antibodies for syphilis or HIV to be detectable.</li></ul></li><li><strong>Reassure girls and young women about possible adverse effects </strong>of hormonal contraceptives, for example:<ul><li><strong>Weight gain</strong> — Weight gain may occur with the progestogen-only injectable, depot medroxyprogesterone acetate (DMPA). There is no evidence of weight gain with use of COCs or the CTP.<ul><li>However, weight gain is common in all women, and may simply reflect the normal increase in weight expected during the early reproductive years, and with changes in eating habits and activity levels.</li></ul></li><li><strong>Mood</strong> — POPs and COCs may be associated with mood changes, but there is no evidence that they cause depression.</li><li><strong>Bleeding patterns and dysmenorrhoea</strong> — young women should be informed that altered bleeding patterns are common when starting hormonal contraception, especially in the first 3 months of use. However, dysmenorrhoea may improve with use of combined hormonal contraception (CHC).</li><li><strong>Bone mineral density</strong> — bone mineral density is influenced by normal pubertal development, exercise, diet, smoking, and some hormonal contraception.<ul><li>The use of the progestogen-only injectable, depot medroxyprogesterone acetate (DMPA), is associated with a small loss of bone mineral density which is usually recovered after discontinuation.</li><li>Consider the DMPA injection only if all other methods of contraception are unsuitable or unacceptable.</li></ul></li><li><strong>Venous thromboembolism</strong> — the risk of venous thromboembolism is increased with use of COCs, but the absolute risk is very low (5–12 per 10,000 women years). Progestogen-only contraceptives do not appear to increase the risk of venous thromboembolism. </li><li><strong>Return of fertility</strong> — normal fertility returns as soon as most contraceptive methods are stopped. However, there may be a delay in conception after stopping:<ul><li>The combined contraceptive patch or the combined vaginal ring (in some women the delay can be up to a few months).</li><li>The progestogen-only injectable (there could be a delay of up to 1 year in the return of normal fertility).</li></ul></li><li><strong>Risk of cancer</strong>:<ul><li>There is no overall increased risk of cancer with COCs. COCs reduce the risk of ovarian and endometrial cancer and, with less than 5 years' use, do not increase the risk of cervical cancer.<ul><li>There is a small increased risk after 5 years, and a two-fold increase after 10 years, which returns to normal 10 years after stopping the COC.</li></ul></li><li>Any increase in risk of breast cancer associated with hormonal contraception is likely to be very small and reduces after stopping the hormonal contraception.</li><li>The progestogen-only injectable, DMPA, does not appear to have any effect on the risk of ovarian, endometrial, or cervical cancer.</li></ul></li><li>For more information, see the section on risks and adverse effects of <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/#risks-adverse-effects\">progestogen-only contraceptives</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/#risks-adverse-effects\">combined hormonal contraceptives</a> in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li></ul></li></ul><!-- end field 46c7fd41-5b8e-43a6-8af4-7b05b321d520 --><!-- end item 8adab1d7-66d0-4934-a7ae-1ac28861d3f7 -->","subChapters":[{"id":"1e4f20ca-7b0c-5249-9cec-846c106f5bbe","slug":"basis-for-recommendation-7c2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6f55beef-f275-4abb-bcda-d561cfe99bc6 --><h4>Basis for recommendation</h4><!-- end field 6f55beef-f275-4abb-bcda-d561cfe99bc6 -->","summary":null,"htmlStringContent":"<!-- begin item 7c213088-e89a-4384-bc7e-fdac47675d28 --><!-- begin field 1871d566-908a-434e-8aa9-8ce87277360a --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Contraceptive choices for young people</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2010b</a>], <em>Combined hormonal contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2012</a>], <em>Intrauterine contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015a</a>], <em>Progestogen-only implant</em>s [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014b</a>], <em>Progestogen-only injectables</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014c</a>], and <em>Progestogen-only pills</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015d</a>].</p><h5>Hormonal contraceptives and mood changes</h5><ul><li>Depression is listed as an adverse effect of hormonal contraceptives. However, the FSRH advises that while they may be associated with mood changes, there is no evidence that they cause depression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2010b</a>].</li></ul><!-- end field 1871d566-908a-434e-8aa9-8ce87277360a --><!-- end item 7c213088-e89a-4384-bc7e-fdac47675d28 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}